ARPA-H deploys $139M for behavioral health transformation — neuromodulation and digital therapeutics eligible
Summary
ARPA-H named first research teams in its $139M behavioral health initiative, with scope covering novel neuromodulation approaches, AI-driven psychiatric diagnostics, and digital therapeutic platforms for depression, PTSD, addiction, and other psychiatric conditions. Unlike NIH's conservative peer review, ARPA-H funds high-risk, high-reward approaches — positioning it as the federal funding vehicle for the kinds of bold psychiatric neurotech bets that traditional grants and commercial VCs avoid.
Why it matters
ARPA-H entering psychiatric neuromodulation funding creates a new non-dilutive capital source for companies developing novel therapeutic BCIs, closed-loop psychiatric stimulation, and AI-guided neurostimulation. ARPA-H's tolerance for unconventional approaches and its $1.5B+ annual budget makes it potentially the largest federal supporter of psychiatric neurotech innovation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial